MedTrace Logo

The Circulating Cell-free Genome Atlas Study

NCT02889978 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15254

Last updated 2023-09-13

No results posted yet for this study

Summary

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from participants with a new diagnosis of cancer (blood and tumor tissue) and from participants who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer participants and to develop models for distinguishing cancer from non-cancer.

Conditions

Sponsors & Collaborators

  • GRAIL, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Fung, MD, PhD · GRAIL, Inc.

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-04
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02889978 on ClinicalTrials.gov